Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 274
- Registration Number
- NCT00101712
- Locations
- π¨π
Novartis Investigative Site, Basel, Switzerland
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
- Conditions
- Osteoporosis
- First Posted Date
- 2005-01-04
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 802
- Registration Number
- NCT00100620
- Locations
- πΊπΈ
McGuire VA Medical Center, Richmond, Virginia, United States
πΊπΈUnited Osteoporosis Centers, Gainesville, Georgia, United States
πΊπΈCenter for Education and research on Therapeutics (CERTs) of Musculoskeletal Disorders, Birmingham, Alabama, United States
Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis
- Conditions
- Osteoporosis
- First Posted Date
- 2005-01-04
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 676
- Registration Number
- NCT00100607
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
- Conditions
- Osteoporosis
- First Posted Date
- 2005-01-04
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT00100555
- Locations
- πΊπΈ
St. Luke's Episcopal Hospital Ctr for Ortho. Res. and Education, Houston, Texas, United States
πΊπΈUniv. of Alabama/Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, United States
πΊπΈDenver Arthritis Clinic, Denver, Colorado, United States
Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 717
- Registration Number
- NCT00099918
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
π©πͺNovartis Investigative Sites, Investigative Centers, Germany
Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 544
- Registration Number
- NCT00099892
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 515
- Registration Number
- NCT00099944
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 254
- Registration Number
- NCT00099931
- Locations
- π©πͺ
Novartis Investigative Site, Investigative Sites, Germany
A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT00099957
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 639
- Registration Number
- NCT00099905
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States